Sickle cell disease damages the cardiovascular system through multiple, overlapping pathways that affect everything from the smallest capillaries to the heart muscle itself. The misshapen red blood cells that define the condition do not just clog tiny vessels; they trigger a cascade of inflammation, destroy nitric oxide (a molecule that keeps blood vessels relaxed), stiffen arteries prematurely, and force the heart to work harder for years on end. Over time, these insults accumulate into serious complications including pulmonary hypertension, silent strokes, heart muscle scarring, and abnormal heart rhythms.
How Sickle-Shaped Cells Damage Blood Vessels
The root of the cardiovascular harm begins with hemoglobin S, the abnormal form of the oxygen-carrying protein inside red blood cells. When oxygen levels drop even slightly, hemoglobin S molecules clump together into rigid polymer chains, distorting the red blood cell into its characteristic crescent or sickle shape. These stiffened cells lose the flexibility they need to squeeze through narrow capillaries, and they become unusually sticky, adhering to the walls of blood vessels and to other blood cells.1Blood. Hypoxia Impact on Red Blood Cell-Mediated Microvascular Occlusion and Adhesion in Sickle Cell Disease and Sickle Cell Trait That stickiness, combined with the cells’ inability to deform, is what causes vaso-occlusive episodes, the painful crises that are the hallmark of the disease. But these episodes are not just painful events. Each one represents a burst of vascular injury.
The damage extends beyond the mechanical blockage. Sickled red blood cells are fragile and break apart more easily than normal cells, a process called hemolysis. When they rupture, they spill free hemoglobin into the bloodstream. That free hemoglobin rapidly scavenges nitric oxide, a signaling molecule that tells blood vessel walls to relax and dilate.2PubMed Central. Sickle cell disease and nitric oxide: a paradigm shift? Without enough nitric oxide, vessels constrict, blood flow drops, and the stage is set for further oxygen deprivation and more sickling. Free hemoglobin also generates oxidative stress, which damages the inner lining of blood vessels and promotes inflammation.3JCI Insight. Intravascular hemolysis and the pathophysiology of sickle cell disease The result is a self-reinforcing loop: sickling causes hemolysis, hemolysis destroys nitric oxide, nitric oxide loss causes vasoconstriction, vasoconstriction worsens sickling.
On top of all this, the vessel walls themselves become chronically inflamed. Adhesion molecules on the surface of endothelial cells (the cells lining blood vessels) stay turned up far higher than normal, making it easier for sickled red cells, white blood cells, and platelets to stick and pile up at vascular walls.4PubMed Central. Differential expression of adhesion molecules in sickle cell anemia and gut microbiome effect This chronic endothelial activation is not limited to crisis periods. It persists between crises, steadily wearing down vascular health even when a person feels relatively well.
What Happens to the Heart Muscle
Because sickle cell disease causes chronic anemia, the heart has to pump harder and faster to deliver adequate oxygen to the body. Over years, this extra workload leads to enlargement of the heart chambers, particularly the left ventricle. That enlargement, while initially compensatory, eventually becomes a liability as the heart muscle remodels in unhealthy ways.
One of the more recently appreciated forms of heart damage in sickle cell disease is diffuse myocardial fibrosis, the replacement of normal heart muscle with scar-like tissue. A cardiac MRI study found that this fibrosis was markedly increased in sickle cell anemia patients compared to healthy controls, and roughly seven in ten participants showed diastolic abnormalities, meaning their hearts had trouble relaxing and filling properly between beats. Patients with the most fibrosis were more likely to have true diastolic dysfunction and enlarged left atria.5PubMed Central. Association between diffuse myocardial fibrosis and diastolic dysfunction in sickle cell anemia This matters because diastolic dysfunction can eventually progress to heart failure, specifically the kind where the heart pumps with normal or near-normal strength but cannot fill adequately.
The fibrosis does not just stiffen the ventricle. It also impairs the left atrium, the chamber that feeds blood into the left ventricle. Research using advanced cardiac imaging showed that as ventricular fibrosis worsened, the left atrium became stiffer and its pumping efficiency declined.6Scientific Reports. Left atrial dysfunction in sickle cell anemia is associated with diffuse myocardial fibrosis, increased right ventricular pressure and reduced exercise capacity Patients with the most fibrosis also had higher pressures in the right side of the heart and reduced exercise tolerance. The picture that emerges is of a heart slowly losing its flexibility and efficiency, often without obvious symptoms until the damage is advanced.
Pulmonary Hypertension and the Risk of Death
Among the most dangerous cardiovascular complications is pulmonary hypertension, which is elevated blood pressure in the arteries supplying the lungs. Screening studies have found that roughly a quarter of adults with sickle cell disease have elevated pressures by echocardiographic estimates.7PubMed Central. Prevalence and risk factors for pulmonary artery systolic hypertension among sickle cell disease patients in Nigeria The condition is thought to develop largely through the same nitric oxide depletion and vascular remodeling already described, with chronic hemolysis as a major driver.
The mortality signal is stark. A landmark study found that patients whose echocardiographic screening suggested pulmonary hypertension had a roughly tenfold increased risk of death compared to those with normal readings.8PubMed. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease When pulmonary hypertension was confirmed by more invasive testing, the six-year mortality reached about 37%, compared to roughly 13% in those without it.9PubMed Central. Mortality in Adults With Sickle Cell Disease and Pulmonary Hypertension Clinicians can screen for elevated pulmonary pressures using a standard echocardiogram that measures a value called tricuspid regurgitant jet velocity, essentially a Doppler-based estimate of pressure in the right side of the heart.10SpringerLink / Paediatr Drugs. Clinical Study to Evaluate the Possible Efficacy and Safety of L-Arginine in Children with Sickle Cell Disease and Increased Tricuspid Regurgitant Jet Velocity: a Randomized Controlled Trial
What makes pulmonary hypertension in sickle cell disease particularly frustrating is that it appears resistant to standard treatments for other causes of pulmonary hypertension. And unlike some complications that respond to hydroxyurea therapy, elevated pulmonary pressures in sickle cell disease have not consistently improved with this drug. Catching it early through routine echocardiographic screening remains the most practical step.
The Blood Pressure Paradox
People with sickle cell disease tend to have lower blood pressure than the general population, a fact that might sound protective. It is not as reassuring as it seems. Researchers have identified a phenomenon called “relative systemic hypertension,” in which organ damage typically associated with high blood pressure, such as kidney failure and pulmonary hypertension, starts appearing at blood pressure readings that would be considered completely normal in anyone else. In sickle cell disease, a systolic reading around 120 to 139 or a diastolic reading of 70 to 89 can be associated with complications that ordinarily would require much higher pressures to cause.11PubMed Central. Factors associated with blood pressure variation in sickle cell disease patients: a systematic review and meta-analysis
The reasons are still being worked out, but the gist is that chronic vascular dysfunction and impaired nitric oxide signaling mean the blood vessels of someone with sickle cell disease are already operating under stress. Even modest pressure loads, ones a healthy vasculature shrugs off, push these compromised vessels past their limits. The practical implication is that clinicians who manage sickle cell patients cannot simply use the same blood pressure thresholds they use for the general population. What looks like a “normal” reading may already be causing harm.
Arterial Stiffness and Accelerated Vascular Aging
Paradoxically, while blood pressure runs low, the arteries of sickle cell patients show signs of accelerated aging. The multinational African CADRE study found that a standard measure of large-artery stiffness, pulse wave velocity, was actually lower in sickle cell patients than in controls. However, a different measure called the augmentation index, which captures how reflected pressure waves from stiff peripheral arteries add to the central blood pressure, climbed faster with age in sickle cell patients than in healthy adults.12PubMed. Arterial Stiffness Impairment in Sickle Cell Disease Associated With Chronic Vascular Complications: The Multinational African CADRE Study In plain terms, the large elastic arteries may initially be more compliant because of chronic anemia and high cardiac output, but the smaller arteries downstream are stiffening prematurely. Over time, this mismatch worsens the load on the heart and contributes to the diastolic dysfunction described earlier.
Stroke and Silent Brain Infarcts
The brain is one of the organs most vulnerable to the vascular injury of sickle cell disease. Overt stroke, where a person suddenly loses function, affects a meaningful fraction of patients, especially children. But even more common are silent cerebral infarcts: areas of brain tissue that have been damaged without producing obvious neurological symptoms. A systematic review and meta-analysis found that the pooled prevalence of these silent infarcts in patients with the most severe genotypes was about 30%, while milder genotypes showed a prevalence closer to 9%.13PubMed Central. Silent cerebral infarcts in patients with sickle cell disease: a systematic review and meta-analysis That means roughly one in three people with severe sickle cell disease has brain damage detectable on an MRI scan, even if they seem neurologically fine on the surface.
These silent infarcts are not truly benign. They are associated with cognitive difficulties, lower academic performance in children, and an increased risk of future overt strokes. Transcranial Doppler ultrasound, which measures blood flow velocity in the brain’s large arteries, is used in children with sickle cell disease to identify those at highest stroke risk. When velocities are abnormally high, indicating narrowed arteries, chronic blood transfusions can dramatically reduce the chance of a first stroke. A Cochrane review found that long-term transfusion therapy reduced the incidence of clinical stroke by about 88% in high-risk children.14Cochrane Database of Systematic Reviews. Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease That benefit comes at the cost of iron overload and transfusion reactions, but the stroke prevention is substantial enough that screening and transfusion programs are now standard in pediatric sickle cell care in many countries.
Leg Ulcers as a Window Into Microvascular Failure
One of the more visible and debilitating cardiovascular consequences shows up far from the heart: chronic leg ulcers around the ankles. These are not ordinary wounds. They develop because the combination of hemolysis-driven nitric oxide depletion, oxidative stress, and impaired skin blood flow creates conditions where even minor trauma can lead to a wound that refuses to heal.15PubMed. Controversies in the pathophysiology of leg ulcers in sickle cell disease The ulcers tend to resemble arterial ulcers, with poor blood supply to the wound bed being a central problem.
Studies measuring microvascular function in the skin have confirmed that patients with active leg ulcers have measurably worse microcirculation than sickle cell patients without ulcers. Oxygen delivery to the skin tissue is lower, and the tiny blood vessels respond poorly to stimuli that would normally cause them to widen.16PubMed Central. Impaired microvascular function in patients with sickle cell anemia and leg ulcers improved with healing The encouraging finding from this research is that when ulcers do heal, the microvascular function partially recovers, suggesting the impairment is not entirely permanent. Still, sickle cell leg ulcers are notoriously difficult to treat and can persist for months or years, significantly affecting quality of life.
Heart Rhythm and Autonomic Dysfunction
Heart rhythm disturbances are an underappreciated piece of the cardiovascular picture in sickle cell disease. The autonomic nervous system, the network that regulates heart rate, blood pressure, and other involuntary functions, appears to be impaired in a substantial proportion of patients. One study found evidence of autonomic dysfunction in roughly 58% of adult sickle cell patients tested, while all healthy controls had normal results.17Elsevier / ScienceDirect (Archives of Cardiovascular Diseases). Cardiac rhythm disorders in sickle cell disease: A literature review This autonomic imbalance can shift the heart toward prolonged QT intervals (a measure on an ECG that, when stretched, increases arrhythmia risk) and may contribute to both atrial and ventricular rhythm disturbances.
The clinical concern is sudden cardiac death. In other conditions where autonomic dysfunction is well documented, such as diabetes and heart failure, the link to sudden death is firmly established. Researchers have raised the possibility that autonomic dysfunction represents an underrecognized risk factor for sudden cardiac death in sickle cell disease as well.17Elsevier / ScienceDirect (Archives of Cardiovascular Diseases). Cardiac rhythm disorders in sickle cell disease: A literature review The combination of myocardial fibrosis providing a substrate for abnormal electrical circuits, plus autonomic dysfunction disturbing the heart’s rhythm regulation, is a worrisome pairing that deserves more research attention.
Exercise Risk in Sickle Cell Trait
A related but distinct issue involves people who carry sickle cell trait, meaning they have one copy of the hemoglobin S gene rather than two. Sickle cell trait is generally considered benign, and the vast majority of carriers live without any sickle-related health problems. However, there is a well-documented risk of sudden death during extreme physical exertion, particularly in military training and competitive athletics.18PubMed Central. Sickle Cell Trait and Sudden Death The condition has been called exercise collapse associated with sickle cell trait, or ECAST.19PubMed. Exercise collapse associated with sickle cell trait (ECAST): case report and literature review
The mechanism is thought to involve sickling of red blood cells during intense, sustained exertion, especially in hot conditions or at altitude, when oxygen levels in working muscles drop sharply. The sickling can cause sudden vascular obstruction and metabolic collapse. This risk does not apply to moderate exercise and should not discourage carriers from being physically active. The danger is specific to maximal or near-maximal sustained effort, particularly when combined with dehydration or heat stress. Awareness and simple precautions, such as adequate hydration, gradual buildup in training intensity, and immediate medical response to signs of collapse, have proven effective at reducing these events in military and athletic settings.
Pregnancy and Compounded Cardiovascular Strain
Pregnancy imposes major cardiovascular demands on any person, increasing blood volume by about 50% and cardiac output substantially. For someone with sickle cell disease, these demands land on a cardiovascular system already under chronic stress. When preeclampsia, a dangerous pregnancy complication involving high blood pressure and organ damage, occurs on top of sickle cell disease, the combined effects on the vasculature are amplified. Both conditions involve endothelial damage and inflammation, and their overlap creates heightened risks for the heart and blood vessels of both the mother and the fetus.20PubMed Central. Echocardiographic and platelet markers of cardiovascular strain in sickle cell disease with superimposed preeclampsia: a perspective
Pregnant individuals with sickle cell disease are at increased risk for worsening anemia, more frequent vaso-occlusive crises, venous thromboembolism, and cardiac strain. Echocardiographic monitoring during pregnancy can help clinicians detect rising right heart pressures or worsening diastolic function early enough to intervene. This population represents one of the clearest examples of how sickle cell disease does not exist in a vacuum: any additional cardiovascular insult, whether pregnancy, infection, or surgery, lands on a system with far less reserve than normal.
Treatments That Target Cardiovascular Damage
Four disease-modifying drugs are currently approved for sickle cell disease: hydroxyurea, L-glutamine, crizanlizumab, and voxelotor.21PubMed Central. Promising role of voxelotor in managing sickle cell disease in children: a narrative review Each works differently. Hydroxyurea boosts production of fetal hemoglobin, which interferes with the polymerization of hemoglobin S and reduces sickling. L-glutamine is an amino acid thought to reduce oxidative stress in red blood cells. Crizanlizumab blocks P-selectin, one of the adhesion molecules that helps sickled cells stick to vessel walls, thereby reducing vaso-occlusive crises. Voxelotor directly inhibits hemoglobin S polymerization by increasing hemoglobin’s affinity for oxygen.
From a cardiovascular standpoint, the rationale for each of these drugs connects back to the vascular injury pathways covered earlier. Anything that reduces sickling or hemolysis should, in theory, preserve nitric oxide, reduce chronic inflammation, and slow the accumulation of organ damage. Hydroxyurea has the longest track record and the strongest evidence base for reducing acute complications, though its effect on pulmonary hypertension has been disappointing. Chronic blood transfusion therapy remains the best-proven intervention for stroke prevention in children, as already noted, and is also used in adults with severe anemia or recurrent crises.
Gene therapy and gene editing approaches are also moving forward, with the first CRISPR-based therapy receiving regulatory approval in some countries. These treatments aim to either correct the sickle mutation or reactivate fetal hemoglobin production permanently, which would address the upstream cause of all the cardiovascular damage. Early results have been promising, though long-term cardiovascular outcomes in treated patients are still being tracked. For now, the practical reality for most people with sickle cell disease is a combination of one or more of the approved medications, screening for pulmonary hypertension and stroke risk, and close monitoring of heart function over time.